Vimpat and Type 1 diabetes - a phase IV clinical study of FDA data

Summary:

Type 1 diabetes is reported as a side effect among people who take Vimpat (lacosamide), especially for people who are female, 50-59 old, have been taking the drug for < 1 month also take Dilantin, and have Depression.

The phase IV clinical study analyzes which people have Type 1 diabetes when taking Vimpat. It is created by eHealthMe based on reports of 20,279 people who have side effects when taking Vimpat from the FDA, and is updated regularly.

What is Vimpat?

Vimpat has active ingredients of lacosamide. It is often used in epilepsy. eHealthMe is studying from 20,832 Vimpat users. Check the latest studies of Vimpat.

What is Type 1 diabetes?

Type 1 diabetes is found to be associated with 668 drugs and 1,644 conditions by eHealthMe. Check the latest studies of Type 1 diabetes.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Jul, 23, 2026

20,279 people reported to have side effects when taking Vimpat.
Among them, 16 people (0.08%) have Type 1 diabetes.

Among these 16 people:

How long have people been on Vimpat when they have Type 1 diabetes? *

What is the gender of people who have Type 1 diabetes when taking Vimpat? *

female: 81.25 %
male: 18.75 %

What is the age of people who have Type 1 diabetes when taking Vimpat? *

What are other drugs people take besides Vimpat? *

What are other side effects people have besides Type 1 diabetes? *

Irritability: 6 people, 37.50%
Drug Intolerance (drug sensitivity): 6 people, 37.50%
Diabetic Ketoacidosis (diabetic ketoacidosis (dka) is high concentrations of ketone bodies): 5 people, 31.25%
Depression: 4 people, 25.00%
Fatigue (feeling of tiredness): 4 people, 25.00%
Coordination Abnormal (abnormal movement): 4 people, 25.00%
Gait Disturbance: 4 people, 25.00%
Confusional State: 4 people, 25.00%
Heart Rate Decreased: 4 people, 25.00%
Fall: 4 people, 25.00%

What are the existing conditions these people have? *

Depression: 3 people, 18.75%
Tuberous Sclerosis (a rare genetic disease that causes benign tumours to grow in the brain and other organs): 1 person, 6.25%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 1 person, 6.25%
Cystic Fibrosis (disease of the secretary glands): 1 person, 6.25%
Bronchiectasis (abnormal widening of the bronchi or their branches, causing a risk of infection): 1 person, 6.25%
Brain Neoplasm Benign (non-cancerous tumour of brain): 1 person, 6.25%
Astrocytoma, Low Grade (low grade tumour of the brain that originate in a particular kind of glial-cells): 1 person, 6.25%

* Approximation only. Some reports may have incomplete information.

Do you take Vimpat and have Type 1 diabetes?

- Check whether Type 1 diabetes is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Vimpat:

Vimpat (20,832 reports)

Type 1 diabetes treatments and more:

Type 1 diabetes (46,846 reports)

Browse all side effects of Vimpat:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Type 1 diabetes:

Type 1 diabetes (668 drugs)

Browse all the conditions that are associated with Type 1 diabetes:

Type 1 diabetes (1,644 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on lacosamide (the active ingredients of Vimpat) and Vimpat (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.